-
公开(公告)号：KR1020160053609A
公开(公告)日：2016-05-13
申请号：KR1020140152894
申请日：2014-11-05
Applicant: 서울대학교산학협력단
IPC: C07K14/315 , C07K14/195 , G01N33/53
CPC classification number: C07K14/315 , C07K14/195 , C12N15/11 , G01N33/53
Abstract: 본발명은단백질 G-링커결합체, 상기단백질 G-링커결합체가고체지지물질의표면에결합된바이오칩또는바이오센서, 및바이오칩또는바이오센서를이용하여항원을분석하는방법에관한것이다. 본발명의단백질 G-링커결합체로인해항체의방향성을조절하면서선택적으로표지가가능하게되어, 항원-항체결합부위를방해하지않으면서항체를센서표면에고정할수 있다.
Abstract translation: 本发明涉及蛋白质G-接头缀合物，生物芯片或生物传感器，其上蛋白质G-接头缀合物与固体支持材料的表面结合，以及使用生物芯片或生物传感器分析抗原的方法。 蛋白质G-接头缀合物能够在调节抗体取向的同时实现选择性标记。 因此，可以将抗体固定在传感器的表面上，而不会阻塞抗原和抗体的结合位点。
-
公开(公告)号：KR1020160017934A
公开(公告)日：2016-02-17
申请号：KR1020140101643
申请日：2014-08-07
Applicant: 서울대학교산학협력단 , 경북대학교 산학협력단 , 경북대학교병원
IPC: A61K31/5025 , A61K31/50 , A61P29/00
CPC classification number: A61K31/5025 , A61K31/503 , A61K45/06 , A61K2300/00
Abstract: 본발명은벤조피라닐테트라사이클화합물을포함하는항염증약학적조성물에관한것이다. 본발명에따르면, 상기화학식 1로표시되는화합물은염증유발인자인 HMGB 단백질의번역후 수식을효과적으로저해함으로써우수한염증억제를가지며, 이로인하여염증관련질환에대하여높은치료효과또는예방효과를갖는약학적조성물이제공될수 있다.
Abstract translation: 本发明涉及包含苯并吡喃基四环化合物的抗炎药物组合物。 根据本发明，由化学式1表示的化合物通过在作为炎症诱导因子的HMGB蛋白质的翻译后有效抑制修饰而具有优异的炎症抑制，从而提供具有高治疗效果或预防效果的药物组合物 尊重炎症相关疾病。
-
公开(公告)号：KR1020140012259A
公开(公告)日：2014-02-03
申请号：KR1020120078596
申请日：2012-07-19
Applicant: 전남대학교산학협력단 , 서울대학교산학협력단
IPC: A61K39/395 , A61K48/00 , A61P9/00
CPC classification number: A61K38/00 , A61K31/711
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cardiomegaly-associated diseases, wherein the composition comprises an estrogen-related receptor gamma (ERR γ) inhibiting material as an active ingredient. A compound or oligonucleotide contained in the composition of the present invention is involved in signal down-regulation of ERR γ or directive expression of ERR γ, thereby inhibiting functions of ERR γ. In particular, the compound GSK5182 and oligonucleotide of the present invention, as a therapeutic agent for treating cardiomegaly, first represents a successful result in the treatment of cardiomegaly-associated diseases, targeting ERR γ. Therefore, the composition for inhibiting cardiomegaly comprising the ERR γ inhibiting material as an active ingredient according to the present invention can contribute to the treatment of cardiomegaly by reducing the expression of genes associated with cardiomegaly and inhibiting the activity of a cardiomegaly regulatory enzyme.
Abstract translation: 本发明涉及用于预防或治疗心脏肥大相关疾病的药物组合物，其中所述组合物包含雌激素相关受体γ（ERRγ）抑制物质作为活性成分。 包含在本发明组合物中的化合物或寡核苷酸涉及ERRγ的信号下调或ERRγ的指示表达，从而抑制ERRγ的功能。 特别是作为治疗心脏病的治疗剂的本发明化合物GSK5182和寡核苷酸首先代表以针对ERRγ为对象的治疗心脏肥大相关疾病的成功结果。 因此，根据本发明的包含ERRγ抑制物质作为活性成分的抑制心脏病的组合物可以通过减少与心脏肥大相关的基因的表达和抑制心脏肥大调节酶的活性来促进心脏肥大的治疗。
-
公开(公告)号：KR101090596B1
公开(公告)日：2011-12-08
申请号：KR1020100029849
申请日：2010-04-01
Applicant: 서울대학교산학협력단
IPC: G01N33/02 , G01N33/58 , C07D487/04 , C07K16/44
Abstract: 본발명은특정유해화학물질종(species)을선택적으로검출하거나특정유해화학물질군(group)에속하는유해화학물질들을비-선택적으로동시에검출하기위한센서의제조방법에관한것으로, 본발명의센서제조방법에따르면, 특정유해화학물질종(species)에대한선택적검출또는특정유해화학물질군(group)에속하는유해화학물질모두에대한비-선택적검출이현장에서용이하게이루어질수 있는센서를보다저렴하면서도신속하게구축할수 있고, 이러한방법으로제조된센서는검출하고자하는특정유해화학물질종 또는유해화학물질군의존재를현장에서신속, 정확하게검출하는데효과적으로활용될수 있다.
-
15.发明公开
公开(公告)号：KR1020110062351A
公开(公告)日：2011-06-10
申请号：KR1020090119049
申请日：2009-12-03
Applicant: 서울대학교산학협력단
IPC: C07D471/02 , C07D487/04
Abstract: PURPOSE: A method for preparing hetero-biaryl pyridine derivative compounds is provided to easily produce the compounds and to suppress tumor cell proliferation. CONSTITUTION: A method for preparing hetero-biaryl pyridine derivative compound of chemical formula 1 comprises a step of reacting a compound of chemical formula 2 with a compound of chemical formula 3 in a polar protic solvent under the presence of acid catalyst. The polar protic solvent is methanol, ethanol, dichloroethane, dimethyl formamide, or mixture thereof. The acid catalyst is AlCl_3, AcOH, formic acid, trifluoroacetic acid(TFA), or HCl.
Abstract translation: 目的：提供制备异环联吡啶衍生物化合物的方法，以容易地制备化合物并抑制肿瘤细胞增殖。 构成：化学式1的异联吡啶衍生物化合物的制备方法包括使化学式2的化合物与化学式3化合物在极性质子溶剂中在酸催化剂存在下反应的步骤。 极性质子溶剂是甲醇，乙醇，二氯乙烷，二甲基甲酰胺或其混合物。 酸催化剂是AlCl 3，AcOH，甲酸，三氟乙酸（TFA）或HCl。
-
Patent Agency Ranking
公开(公告)号：KR101733578B1
公开(公告)日：2017-05-08
申请号：KR1020160049177
申请日：2016-04-22
Applicant: 경북대학교 산학협력단 , 경북대학교병원 , 서울대학교산학협력단
CPC classification number: A61K31/42
Abstract: 본발명은카바모일레이티드우레탄화합물을포함하는신경염증성질환의예방또는치료용조성물에관한것으로, 보다상세하게는미세아교세포(microglia) 또는성상교세포의활성을억제하는효과, 일산화질소(NO) 및 TNF-α의생성을억제하는효과, IL-1β및 iNOS 유전자의발현을억제하는효과를나타내는카바모일레이티드우레탄화합물을포함하는신경염증성질환의예방또는치료용조성물에관한것이다. 본발명에따른카바모일레이티드우레탄화합물은상기와같은효과를나타내어신경염증성질환의예방또는치료에유용하게사용될수 있다.
Abstract translation: 本发明的氨基甲酰基联合涉及一种组合物用于预防或治疗神经系统的炎性疾病，其包括氨基甲酸酯化合物，更具体地，小胶质细胞（小胶质细胞），或作用，一氧化二氮，以抑制星形细胞的活性（NO） 并用于预防或治疗神经性炎性疾病，包括丙交酯表示抑制的效果的表达的效果的氨基甲酰基射线氨基甲酸酯化合物组合物，IL-1β和iNOS基因抑制产生TNF-α的。 根据本发明的氨基甲酰化氨基甲酸酯化合物显示出上述效果并且可以有效地用于预防或治疗神经炎性疾病。
-
公开(公告)号：KR101727634B1
公开(公告)日：2017-04-17
申请号：KR1020130105411
申请日：2013-09-03
Applicant: 서울대학교산학협력단
IPC: C07D261/08 , A61K31/42 , A61P3/10 , A61P29/00
Abstract: 본발명은이속사졸을중심구조로갖는신규화합물및 이의제조방법과, 이속사졸을중심구조로갖는화합물또는이의약학적으로허용가능한염을유효성분으로함유하는 PPAR 감마관련질병치료용약학조성물을제공한다.
-
公开(公告)号：KR101427328B1
公开(公告)日：2014-08-06
申请号：KR1020130029279
申请日：2013-03-19
Applicant: 서울대학교산학협력단
CPC classification number: G01N33/582 , G01N27/447 , G01N33/68
Abstract: Provided of the present invention is a method for identifying a target protein of a physiologically active low molecular compound using a probe and a negative probe labeled with fluorescents having different wavelengths. The probe can be conjugated with a target protein binding to the physiologically active low molecular material and also be conjugated with proteins not binding to the physiologically active low molecular material. Therefore, a negative prove labeled with a fluorescent of a wavelength different from a fluorescent conjugated with the probe can be used, or a physiologically active low molecular substance and the probe can be also used.
Abstract translation: 本发明提供了使用探针和用不同波长的荧光标记的阴性探针鉴定生理活性低分子化合物的靶蛋白的方法。 探针可以与结合生理活性低分子材料的靶蛋白缀合，并且与不结合生理活性低分子材料的蛋白质缀合。 因此，可以使用用与探针结合的荧光波长不同的荧光标记的阴性证明，也可以使用生理活性低分子物质和探针。
-
公开(公告)号：KR1020130030326A
公开(公告)日：2013-03-26
申请号：KR1020120083374
申请日：2012-07-30
Applicant: 서울대학교산학협력단
CPC classification number: C09K11/06 , A61K49/0021 , A61K49/0052 , A61K49/0054 , C07C49/248 , C07C49/255 , C07H15/203 , C09K2211/1011 , C09K19/3469 , H01L51/0052 , H01L51/0062
Abstract: PURPOSE: A high efficiency fluorescence compound is provided to have high single photon absorption and/or two photon absorption characteristic and to not have cytotoxicity. CONSTITUTION: A high efficiency fluorescence compound is indicated in chemical formula 1. In chemical formula 1, R is substituted or unsubstituted naphthalene, substituted or unsubstituted anthracene or substituted or unsubstituted phenalene; R1 is respectively hydrogen, halogen, C1-C6 linear or branched alkyl, C3-C6 cycloalkyl, C1-C6 linear or branched alkoxy, C2-C6 heterocycloalkyl, or substituted or unsubstituted phenyl; and n is 0, 1, 2, or 3.
Abstract translation: 目的：提供高效荧光化合物以具有高单光子吸收和/或两光子吸收特性，并且不具有细胞毒性。 化学式1中，R为取代或未取代的萘，取代或未取代的蒽或取代或未取代的非那非苯; R1分别是氢，卤素，C1-C6直链或支链烷基，C3-C6环烷基，C1-C6直链或支链烷氧基，C2-C6杂环烷基或取代或未取代的苯基; 并且n为0,1,2或3。
-
公开(公告)号：KR101999899B1
公开(公告)日：2019-07-16
申请号：KR1020170136702
申请日：2017-10-20
Applicant: (주)스파크바이오파마 , 서울대학교산학협력단
IPC: C07D491/147 , A61K31/5025
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.024 seconds)
